Clinical Trial Update: Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Zevalin-BEAM/BEAC with autologous stem cell support as consolidation in first-line mantle cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• Carmustine (BiCNU) (carmustine)
• Cytarabine (Ara-C) (cytarabine)
• Etoposide (Etoposide)
• Melphalan (Melphalan)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Oslo University Hospital | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED